MLN-4924

• CAT Number: I005411
• CAS Number: 905579-51-3
• Molecular Formula: C21H25N5O4S
• Molecular Weight: 443.53
• Purity: ≥95%
• Synonyms: Pevonedistat;MLN4924; MLN-4924 ; TAK-924;[(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate
• Target: NEDD8-activating Enzyme
• Solubility: DMSO: ≥ 111.25 mg/mL
• Storage: Store at -20°C
• IC50: 4.7 nM
• InChI: InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1
• InChIKey: MPUQHZXIXSTTDU-QXGSTGNESA-N
• SMILES: C1CC2=CC=CC=C2C1NC3=NC=NC4=C3C=CN4C5CC(C(C5)O)COS(=O)(=O)N

MLN-4924 (Pevonedistat)(CAT: I005411) is a small-molecule inhibitor of NEDD8-activating enzyme (NAE), which plays a key role in the regulation of cullin-RING E3 ubiquitin ligases (CRLs). By inhibiting NAE, MLN-4924 disrupts CRL activity, leading to the accumulation of proteins that cause cell cycle arrest, DNA damage, and apoptosis in cancer cells. This targeted approach has shown promise in treating various cancers, particularly acute myeloid leukemia (AML) and other hematological malignancies. Its ability to selectively inhibit cancer cell growth while minimizing harm to healthy cells makes MLN-4924 a promising candidate in cancer therapy research and clinical trials.